which the accumulation of iodide freshly liberated by catabolism has to be recognized. For this reason the injected protein should have a socalled 'PTA value' of the order of 0-15% and anything above 0 5% greatly complicates the interpretation of the results. Phosphotungstic acid (PTA) is preferred to trichloroacetic acid as precipitant. Ion-exchange resins are effective in reducing fibrinogen PTA values to levels which are satisfactory for this method to be used, and provided they are in the citrate form have no adverse effects on the protein. PTA values which tend to rise during storage of the sterile protein can be brought back to the original value by a second resin treatment.
In the course of analysing the results of 17 recent turnover investigations in which a variety of labelled fibrinogens were used on patients, it was noticed that in only two was a 'bulge' entirely absent from the curve of iodide counts, and these were the only two in which the fibrinogen for labelling had been prepared free of its lowsolubility component. I am indebted to Dr E Regoeczi for drawing my attention to the scanty literature on this material and also for his help in preparing a sample of the rabbit protein which, like the human one, is precipitated by standing in the cold and by ammonium sulphate at 18-19% saturation. His particular interest in it arose out of successful attempts to obtain fibrinogen solutions which could be stored frozen without coagulating or precipitating on thawing. Solutions of low-solubility fibrinogen have a high viscosity and filter slowly and no doubt the relative insignificance of the iodide 'bulges' which were observed in the other 15 experiments reflects the fact that most of this labelled component had been filtered out of the original fibrinogens. Certainly a 311-low-solubility fibrinogen and a 12"I-high-solubility one, both 97% coagulable, gave in the same rabbit entirely different catabolic rates, 70 % of the low-solubility material being catabolized in six hours compared with 10% of the high-solubility one (McFarlane & Regoeczi 1969, unpublished observations). Radioactive Fibrinogen as an Index of Thrombosis A major obstacle to any realistic assessment of the management of thrombosis in the deep veins of the leg has been the lack of a method which will measure the true incidence and natural history of the thrombi. So long as reliance is placed on clinical signs, which are notoriously unreliable in this condition (Sevitt 1968) , many patients will be needlessly exposed to the dangers of anticoagulant or thrombolytic therapy while others are left untreated to face the possibility of fatal embolism. This unsatisfactory situation has been completely altered by the development of fibrinogen preparations labelled with radioactive iodine which behave after injection in all respects as the unlabelled protein (McFarlane 1957) . External scintillation counters can be used to monitor the incorporation of this fibrinogen into thrombi.
Ambrus et al. (1957) produced radioactive thrombi in experimental animals by injecting 1311_ labelled fibrinogen followed by thrombin into artificially occluded segments of vessels. Local radioactivity was measured for up to seven days while the thrombi were exposed to various enzymes and was found to decrease in direct proportion to the reduction in size of the thrombus determined by direct observation. If the thrombi remained intact there was no change in radioactivity during the whole period of observation. Hobbs & Davies (1960) showed a selective concentration of radioactivity in thrombi when (Fig 1) .
A recent trial of anticoagulant and throipbolytic-ther1py (Kakkar et The isotope scanning procedure, therefore, gives a reliable method for demonstrating the incidence and also the fate of thrombi in the deep leg veins. This objective assessment is capable of wide application and can be matched against methods of prophylaxis, or of treatment, or against the results of laboratory tests which may or may not be useful in predicting thrombosis.
Dr George P McNicol (University Department ofMedicine, Glasgow Royal Infirmary)
Measurement During Fibrinolytic Therapy
During therapy with plasminogen activators, major changes may occur in the fibrinolytic enzyme system, in the coagulation mechanism and in platelet function. While this approach to therapy is still under trial, it is desirable to monitor such changes and to define as precisely as possible the biochemical state in each patient treated. It is also essential to the eventual acceptance of thrombolytic therapy to have controlled clinical trials of sound design with adequate objective criteria of benefit.
General comments on methodology: At the present time methods in blood coagulation and more especially in fibrinolysis are not tools of precision. Even where specific factors or components can be assayed, end-points may be unsatisfactory, e.g. clot formation or clot lysis. Where sensitive and precise techniques are available, the urgency of the clinical situation, or lack of laboratory facilities may limit their use.
From a large number of techniques available, those which seem most reliable and straightforward have been selected for discussion.
Plasminogen activator: The intention during therapy with streptokinase or urokinase is greatly to increase the physiological level of plasminogen activator in the plasma and so substantially speed up clearance of fibrin deposits from the vascular compartment. It is clearly highly desirable to have a rapid, simple and reliable method for estimation of plasminogen activator in plasma. Unfortunately no such method exists. Methods which are suitable for use in purified systems present problems when activator in plasma Is under assay.
Methods which use plasma clot lysis times depend not only on plasminogen activator levels, but also on levels of plasminogen and fibrinogen which-may be highily abnormal during therapy. When plasminogen is substantially depleted during streptokinase therapy, lysis times may be much prolonged even in the presence of large concentrations of plasminogen activator. Clot lysis methods have the advantage of simplicity; to obtain a rapid answer, a euglobulin clot lysis technique can be used (e.g. Nilsson & Olow 1962 , Celander & Guest 1964 ).
The 'fibrin plate' test is simple and measures the property which therapy is designed to impart to the plasma, that is the ability to lyse preformed fibrin. Unfortunately plates require many hours' incubation, and so are unsuitable for concurrent control of therapy (Brakman 1967).
The isotopic assay for plasminogen activator (e.g. Fletcher 1964) is simple and rapid, provided isotope equipment and a suitable labelled fibrinogen substrate are available. The technique is not susceptible to the fallacies inherent in methods using the patients' or human plasma. Accurate work awaits the availability of a suitable standardized fibrinogen substrate on a national basis.
Other methods for assay of plasminogen activator, e.g. clot lysis techniques with a standardized fibrinogen solution or the use of synthetic substrates, are suitable only for the assay of concentrated solution in vitro.
Inhibitors of plasminogen activation: No satisfactory routines are available which can differentiate between inhibitors of activation and antiplasmin activty; Streptokinase dose prediction tests: Because of the wide variation in levels of antibody to streptokinase, it is necessary for therapy with this activator either to administer a very large initial dose which will neutralize antibody in the majority of patients (Verstreate et al. 1966) or to calculate an individual antibody-neutralizing dose with which to initiate therapy by the streptokinase sensitivity test (Johnson et al. 1957) .
